Dostarlimab Medicine 03 December 2024 Extended indication MMRp EC Therapeutic value No estimate possible yet Total cost Registration phase Unknown Product Active substance Dostarlimab Domain Oncology Reason of inclusion Indication extension IND Main indication Oncology other Extended indication MMRp EC Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer GSK Portfolio holder GSK Mechanism of action Unknown Route of administration Unknown Therapeutical formulation Unknown Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Unknown Particularity Unknown ATMP No Submission date May 2024 Expected Registration March 2025 Orphan drug Unknown Registration phase Unknown Reimbursement Medicine sluice Additional remarks Het voorgenomen label is nog niet bekend. Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks